Mesocaïne

Lidocaine Hydrochloride, the active ingredient in Mesocaïne, is a local anesthetic presented as a sterile solution for intra‑arterial, intravenous use. It provides rapid local anesthesia and can be used to manage certain cardiac arrhythmias in adult patients.

GNH USA supplies Mesocaïne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidocaine Hydrochloride is used in clinical settings that require rapid local anesthesia or cardiac rhythm control.

- Local anesthesia for minor surgical or diagnostic procedures: provides rapid onset numbing of targeted tissue. - Management of ventricular arrhythmias: stabilizes cardiac electrical activity during acute episodes. - Treatment of acute pain during surgery or postoperative period: reduces pain perception when administered intravenously.

Lidocaine may cause a range of adverse reactions, from mild to severe, depending on dose, route, and patient factors.

Common Side Effects: - Tingling or numbness at the injection site - Dizziness or light‑headedness - Nausea or vomiting - Metallic taste in the mouth - Mild hypotension - Transient visual disturbances

Serious or Rare Side Effects: - Seizures or convulsions - Cardiac arrest or severe bradycardia - Anaphylactic or severe allergic reactions - Methemoglobinemia - Respiratory depression - Persistent arrhythmias

When using Mesocaïne, clinicians should observe several safety measures.

- Cardiac assessment: evaluate baseline ECG and cardiac history before administration. - Hepatic function: adjust dosing in patients with significant liver impairment. - Hypersensitivity: avoid use in individuals with known lidocaine allergy. - Concomitant drugs: monitor closely when combined with other sodium channel blockers. - Dosage monitoring: observe for signs of systemic toxicity during infusion. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Lidocaine can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): additive cardiac toxicity. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase lidocaine plasma levels. - Beta‑adrenergic blockers (e.g., propranolol): may exacerbate bradycardia and hypotension.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., rifampin): may lower lidocaine concentrations. - Other local anesthetics (e.g., bupivacaine): risk of cumulative systemic toxicity.